Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARICENTRE: Baricitinib in Rheumatoid Arthritis
NCT05238896Phase 4Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2022
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Percentage of accurate responses in facial emotion recognition task at Day 1. Started Jun 2022; status: terminated.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05238896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238896.